Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: Imunohistochemical Analysis is Predicitve of Response to Chemotherapy

Authors

  • Daniel Herchenhorn Médico Oncologista Clínico. Hospital do Câncer. Instituto Nacional de Câncer (INCA). Rio de Janeiro (RJ), Brasil.
  • Lídia Magalhães Rezende Patologista. Serviço da Anatomia Patológica. Hospital do Câncer. Instituto Nacional de Câncer (INCA). Rio de Janeiro (RJ), Brasil.
  • Luiz Cláudio Thuler Médico Epidemiologista. Serviço de Pesquisa Clínica. Hospital do Câncer. Instituto Nacional de Câncer (INCA). Rio de Janeiro (RJ), Brasil.
  • Raquel C. Maia Médica Hernatologista. Hospital do Câncer. Instituto Nacional de Câncer (INCA). Rio de Janeiro (RJ), Brasil.
  • Morvan Medina Médico Mastologista. Hospital do Câncer. Instituto Nacional de Câncer (INCA). Rio de Janeiro (RJ), Brasil.
  • Mário Alberto Dantas da Costa Médico Oncologista Clínico. Hospital do Câncer. Instituto Nacional de Câncer (INCA). Rio de Janeiro (RJ), Brasil.

DOI:

https://doi.org/10.32635/2176-9745.RBC.2000v46n2.3414

Keywords:

Locally Advanced Breast Cancer, Neoadjuvant Chemotherapy, Biological Markers

Abstract

Neoadjuvant chemotherapy is the standard initial treatment for locally advanced breast cancer, and correlation between response to chemotherapy and prognostic factors may be useful in this disease. From September 1996 to December 1997, 25 patients with breast cancer stage IlIA, IIIB and inflammatory were submitted to 4 cycles of neoadjuvant chemotherapy consisting of doxorubicin 60mg/m² and cyclophosphamide 600mg/² every 3 weeks, Patey mastectomy and adjuvant treatment. Clinical and pathological responses were related to biological markers studied by imunohistochemical analysis. The markers analyzed were: hormonal receptors, p53, HER/neu (cerb-B2), MIB, nuclear grade and PCNA. Objective clinicai response was 74%. Twenty one out of 23 patients (91%) were operated. Four patients had a complete response on the breast (19%), and two of them also had no axillary disease; 4 patients had residual tumor of less then 2 cm (19%). All markers were overexpressed. Overexpression of p53 and MIB on imunohistochemical analysis had an association with response to neoadjuvant chemotherapy, but it was not statistically significant. There was a positive relation between p53 and clinicai and pathological response that was not found in previous studies. Besides p53, MIB overexpression was also related to a favorable pathological response.

Downloads

Download data is not yet available.

References

AMERICAN JOINT COMMITTEE ON CANCER. Manual of staging of cancer. Philadelphia: J.B.Lippincott Co., 4th ed, 1992.

HARRIS, JR.; MORROW, M.; BONADONNA, G. Cancer of the Breast. In: De Vita VT, Hellman S, Rosenberg AS. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott. 5th edittion vol 2: 1557-1616, 1997.

BONADONNA, G.; VALAGUSSA, R; ZAMBETTI, M.; et al. Prognostic factors in localy advanced noninflammatory breast cancer.Long-term results following primary chemotherapy. Breast Cancer Research and Treatment, 15: 137-147, 1990. DOI: https://doi.org/10.1007/BF01806351

FISHER B, MAMOUNAS E. et al.; Preoperative chemotherapy: a model for studyng the biology and therapy of primary breast cancer. Journal of Clinical Oncology, vol 13, 3: 537-540, 1995. DOI: https://doi.org/10.1200/JCO.1995.13.3.537

ROSEN, P.P. Breast Pathology. Philadelphia: Lippincott-Raven Publishers, 1997.

MAIA, RC.; RUMJANEK, VM. Importância clínica da resistência a múltiplas drogas nas leucemias agudas. Rev Ass Med Brasil, 42(2); 101-108, 1996.

HONKOOP, AH.; VAN DIEST, PJ.; JONG, JS.- Prognostic role of clinical, pathological and biological characteristics in patients with local advanced breast cancer. Br. J. Cancer, 77(4); 621-26, 1998. DOI: https://doi.org/10.1038/bjc.1998.99

LINN, C.; PINEDO, HM.; HONKOOP, AH.- Expression of drug resistance proteins in relation to chemotherapy. Int. J. Cancer, 71: 787-795, 1997. DOI: https://doi.org/10.1002/(SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.0.CO;2-5

PINEDO, HM.; HONKOOP, AH.; VAN DIEST, PJ.; JONG, JS.: p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br Journal Cancer, 74: 63-68, 1996. DOI: https://doi.org/10.1038/bjc.1996.316

BERRUTI, A.; BOTTINI, A.; BERSIGA, M.; et al: p53 expression and reduction in kinetic cell activity in predicting clinical complete response to primary chemotherapy in breast cancer patients. Procedings Americam Soc. of Clinical Oncology, abstr. 393, 1998. DOI: https://doi.org/10.1016/S0959-8049(98)80420-6

KOECHLI, O.; SCHARE, GN.; SEIFERT, B. et al: Mutant p53 protein associated with chemosensivity in breast cancer specimens. Lancet, 344:1647- 1648, 1994. DOI: https://doi.org/10.1016/S0140-6736(94)90447-2

OSBORN, CK.; YOCHMOWITZ, MG.; KNIHT, WA. Et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer, 46: 2884-2888, 1980. DOI: https://doi.org/10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U

THORPE, SM. Prognostic value of steroid hormone receptors: multivariate analysis of systemicaly untreated patients with node negative primary breast cancer. Cancer Research, 47: 6125-6133. 1987.

MANSOUR, EG.; RAVDIN, PM.; DRESSLER, L. Prognostic fictors in early breast cancer. Cancer, 74: 381-400, 1994. DOI: https://doi.org/10.1002/cncr.2820741326

ALFRED, DC.; CLARGK, GM.; MOLINA, R. et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathology, 23: 974-979, 1992. DOI: https://doi.org/10.1016/0046-8177(92)90257-4

CARLOMANGO, C.; BIANCO, AR.; LAURENTTIS, M.; et al.: 20 year update of the Naples Gun Trial of adjuvant breast cancer therapy: evidence of interaction between GerbB-2 expression and Tamoxifen efficacy. Procedings Americam Soc. of Clinical Oncology, abstr. 387, 1998.

SLAMON, D.; LEYLAND-JONES, B.; SHAK, S.; et al.: Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastaric breast cancer markedly increases anticâncer activity. A randomized controlled phase III trial. Procedings American Soc. of Clinical Oncology, abstr. 377, 1998.

GION, M.; MIONE, R.; DITTADI, R. et al: Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. European Journal of Cancer, 31 A: 671-677, 1995. DOI: https://doi.org/10.1016/0959-8049(94)00532-A

LEONG, AS.; LEE, AK. Biological Indices in the assessment of breast cancer. Journal of Clinical Pathology, 48: M221-M238, 1995. DOI: https://doi.org/10.1136/mp.48.5.M221

ROSEN, PP; LESSER, ML.; ARROYO, CD. Et al: p53 in node-negative breast cancer: imunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. Journal of Clinical Oncology, 13: 821-830, 1995. DOI: https://doi.org/10.1200/JCO.1995.13.4.821

BONADONNA, G.; VALAGUSSA P.; BRAMBILLA, C. et al. Primary chemotherapy in operable breast cancer: eight year experience at the Milan Câncer Institute. Journal of Clinical Oncology, 16: 93-100, 1998. DOI: https://doi.org/10.1200/JCO.1998.16.1.93

REMVIKOS, Y; BEUZEBOC, P; ZAJDELA, A.; VOILLEMOT, N. Correlation of pretreatment proliferative activity of breast cancer with response to cytotoxic chemotherapy. J. Nat. Cancer. Inst., 81: 1383-1389, 1989. DOI: https://doi.org/10.1093/jnci/81.18.1383

Downloads

Published

2022-12-15

How to Cite

1.
Herchenhorn D, Rezende LM, Thuler LC, Maia RC, Medina M, Costa MAD da. Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: Imunohistochemical Analysis is Predicitve of Response to Chemotherapy. Rev. Bras. Cancerol. [Internet]. 2022 Dec. 15 [cited 2024 May 19];46(2):163-71. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/3414

Issue

Vol. 46 No. 2 (2000): Apr./May/June

Section

ORIGINAL ARTICLE

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)